Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC).
Grain A, Sirvent A, Strullu M, Françoise M, Mohty M, Guillaume T, Chevallier P, Rialland F. Grain A, et al. Leuk Lymphoma. 2016 Dec;57(12):2937-2941. doi: 10.1080/10428194.2016.1177721. Epub 2016 May 17. Leuk Lymphoma. 2016. PMID: 27184944 No abstract available.
Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant.
Jullien M, Coste-Burel M, Clemenceau B, Letailleur V, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Imbert BM, Ollier J, Grain A, Touzeau C, Moreau P, Béné MC, Vié H, Chevallier P. Jullien M, et al. Among authors: grain a. EJHaem. 2022 Feb 17;3(2):484-487. doi: 10.1002/jha2.398. eCollection 2022 May. EJHaem. 2022. PMID: 35313664 Free PMC article.
Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).
Grain A, Rialland-Battisti F, Chevallier P, Blin N, Dalle JH, Michel G, Dhédin N, Peffault de Latour R, Pochon C, Yakoub-Agha I, Bertrand Y, Sirvent A, Jubert C, Forcade E, Berceanu A, Gandemer V, Schneider P, Bay JO, Rohrlich PS, Brissot E, Paillard C, Plantaz D, Nguyen Quoc S, Gonzales F, Maillard N, Planche L, Baruchel A. Grain A, et al. J Cancer Res Clin Oncol. 2023 Apr;149(4):1473-1483. doi: 10.1007/s00432-022-04021-1. Epub 2022 May 4. J Cancer Res Clin Oncol. 2023. PMID: 35507103
[Can academic structures improve access to CAR-T cells?].
Le Guen C, Grain A, Le Calvez B, Saiagh S, Vrignaud F, Eveillard M, Clémenceau B, Zahar MB. Le Guen C, et al. Among authors: grain a. Bull Cancer. 2024 Jan;111(1):62-72. doi: 10.1016/j.bulcan.2023.10.005. Epub 2023 Nov 28. Bull Cancer. 2024. PMID: 38030508 Review. French.
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial.
Rialland F, Grain A, Labopin M, Michel G, Gandemer V, Paillard C, Pochon C, Clement L, Brissot E, Jubert C, Sirvent A, Rohrlich PS, Plantaz D, Dalle JH, Mohty M. Rialland F, et al. Among authors: grain a. Bone Marrow Transplant. 2022 Nov;57(11):1698-1703. doi: 10.1038/s41409-022-01769-5. Epub 2022 Aug 26. Bone Marrow Transplant. 2022. PMID: 36028757 Clinical Trial.
34 results